Skip to main content

Joan Genescà Ferrer

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Joan Genescà Ferrer

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Chief Liver Unit.
Clinical director of Digestive Diseases.
Professor of Medicine of the UAB.

Projects

Spanish Clinical Research Network (SCReN)

IP: Inmaculada Fuentes Camps
Collaborators: Antonio Moreno Galdó, Tamara Del Rio Higueras, Ariadna Martín Balcells, Olga Sánchez- Maroto Carrizo, Angelica Valderrama Rodríguez, Joan Genescà Ferrer
Funding agency: Instituto de Salud Carlos III
Funding: 319550
Reference: PT17/0017/0030
Duration: 01/01/2018 - 31/12/2020

LIVERHOPE: SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS

IP: -
Collaborators: Ester Palacio Gutierrez, Mª Eulàlia Molinas Guilera, Olga Sánchez- Maroto Carrizo, Amaia Latasa Arrazubi, Joan Genescà Ferrer
Funding agency: EUROPEAN COMMISSION
Funding: 409557
Reference: LIVERHOPE_H2020RTD2016
Duration: 01/01/2017 - 28/02/2023

Sol·licitud d'intensificació per a la dedicació en el projecte "Investigación traslacional en complicaciones de la cirrosis: del modelo experimental a la clínica y viceversa" (PI15/00066).

IP: Sol·licitud d'intensificació per a la dedicació en el projecte "Investigación traslacional en complicaciones de la cirrosis: del
Collaborators: Joan Genescà Ferrer
Funding agency: Instituto de Salud Carlos III
Funding: 18000
Reference: INT16/00109
Duration: 31/01/2017 - 31/12/2017

Efectos de la administración de albúmina en pacientes cirròticos con encefalopatia hepática

IP: Efectos de la administración de albúmina en pacientes cirròticos con encefalopatia hepática
Collaborators: Joan Genescà Ferrer
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: INT15/00040
Duration: 01/01/2016 - 31/12/2016

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

Related professionals

Josefa Mª Heredia Montiel

Josefa Mª Heredia Montiel

Administration and Management
Physiology and Pathophysiology of the Digestive Tract
Read more
Luis Carrera Calderer

Luis Carrera Calderer

Reconstructive Surgery of the Locomotor System
Read more
Nuria Nogués Gálvez

Nuria Nogués Gálvez

Transfusional Medicine
Read more
Anna González Tallada

Anna González Tallada

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.